ANGPT1 and myocardial infarction: To improve the angiogenic properties (endothelial differentiation and angiogenic factor secretion), hMSCs can be genetically modified by overexpressing granulocyte chemotactic protein 2 (GCP-2), angiopoietin-1 (Ang-1), or hepatocyte growth factor to enhance their therapeutic effects on myocardial infarction [45–47].